1. A polypeptide which comprises or consists of the EGF-like domain (EGFLD1), selected from the group consisting of SEQ ID NOs: 140-146, wherein the EGF-like domain may comprise up to 5 deletions, insertions and / or mutations of individual amino acids , wherein the EGF-like domain optionally comprises up to 30 additional amino acids at its C- and / or N-kontse.2. The polypeptide of claim 1, wherein the EGF-like domain (EGFLD1) is selected from the group consisting of SEQ ID NOs: 147-153, wherein the EGF-like domain may comprise up to 13 deletions, insertions and / or mutations of individual aminokislot.3 . The polypeptide of claim 1, wherein the polypeptide further comprises at least one EGF-like domain, each of which is independently selected from the group consisting of SEQ ID NOs: 140-153, wherein each additional EGF-like domain may comprise up to 13 deletions, insertions and / or mutations of individual aminokislot.4. The polypeptide of claim 1, wherein the polypeptide further comprises at least a second EGF-like domain (EGFLD2), selected from the group consisting of SEQ ID NOs: 140-153, wherein the second EGF-like domain may comprise up to 13 deletions, insertions and / or mutations of individual aminokislot.5. The polypeptide of claim 1, wherein the polypeptide further comprises a heparin binding domain (HBD) .6. The polypeptide of claim 5, wherein the heparin-binding domain has the amino acid sequence according to any of SEQ ID NO: 154-157, wherein the heparin-binding domain may comprise up to 12 deletions, insertions and / or mutations of individual aminokislot.7. The polypeptide of claim 5, wherein the heparin-binding domain is at the N-terminus or C-terminus of the EGF-like domena.8. The polypeptide of claim 4, wherein the polypeptide further comprises a linker between the EGF-like domain EGFLD1 and second EGF-like d1. Полипептид, который содержит или состоит из EGF-подобного домена (EGFLD1), выбранного из группы, состоящей из SEQ ID NOs: 140-146, причем
